| Particulars (Rupees in Crores.) | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 |
|---|---|---|---|---|---|
Gross Sales | 8,358.6 | 8,016.1 | 7,672.7 | 7,083 | 7,214.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 8,358.6 | 8,016.1 | 7,672.7 | 7,083 | 7,214.8 |
Other Operating Income | 22.6 | 22.1 | 23.4 | 30.8 | 22 |
Other Income | 154.4 | 313.6 | 193.1 | 201 | 218.9 |
Total Income | 8,535.6 | 8,351.8 | 7,889.2 | 7,314.8 | 7,455.7 |
Total Expenditure | 6,108.2 | 5,961.7 | 5,566.2 | 5,282.6 | 5,213.7 |
PBIDT | 2,427.4 | 2,390.1 | 2,323 | 2,032.2 | 2,242 |
Interest | 81.7 | 75.7 | 59.8 | 59.3 | 39.4 |
PBDT | 2,345.7 | 2,314.4 | 2,263.2 | 1,972.9 | 2,202.6 |
Depreciation | 471.4 | 397 | 380.6 | 367.7 | 373.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 533 | 771.3 | 521.5 | 282.3 | 353.8 |
Deferred Tax | -62.9 | -195.8 | -31.3 | 13.1 | 94.4 |
Reported Profit After Tax | 1,404.2 | 1,341.9 | 1,392.4 | 1,309.8 | 1,380.9 |
Minority Interest After NP | -9.5 | 86.2 | 0 | 0 | 0 |
Net Profit after Minority Interest | 1,413.7 | 1,255.7 | 1,392.4 | 1,309.8 | 1,380.9 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 1,413.7 | 1,255.7 | 1,392.4 | 1,309.8 | 1,380.9 |
EPS (Unit Curr.) | 16.97 | 75.4 | 83.61 | 78.66 | 82.94 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 83.4 | 83.4 | 83.4 | 83.4 | 83.4 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 29.04 | 29.81 | 30.27 | 28.69 | 31.07 |
PBDTM(%) | 28.06 | 28.87 | 29.49 | 27.85 | 30.52 |
PATM(%) | 16.79 | 16.74 | 18.14 | 18.49 | 19.13 |
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
